New Treatment From Shockwave Medical For Clogged Arteries Gets CMS Pass-Through Payment
Starting 1 July, Medicare beneficiaries with a certain type of cardiovascular disease will be able to receive an innovative treatment covered under their government plans.
You may also be interested in...
Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.
After much wrangling, the US agency finally clarified its position on what evidence can determine “intended use” of a product – and industry is not happy.
Fees for filing a premarket application with the US FDA increased 2.5% for fiscal year 2022, which is significantly less than the 7% they went up last year.